# Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct06118788/  
OnCo record `nct06118788` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BG1805 in acute myeloid leukaemia, run by Guangzhou Bio-gene Technology Co., Ltd, now recruiting.

## Summary

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06118788 by Guangzhou Bio-gene Technology Co., Ltd, with 24 participants planned, started 2024-03-07 and due to reach its primary completion in 2027-03. Interventions recorded: BG1805.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06118788
- Phase: 1/2
- Setting: A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Sponsor: Guangzhou Bio-gene Technology Co., Ltd
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06118788: https://clinicaltrials.gov/study/NCT06118788

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)

---
JSON: https://onco.cc/api/v1/entities/nct06118788.json